Mitochondrial amidoxime-reducing component 1 (mARC1) (EC 1.7.-.-) (Molybdenum cofactor sulfurase C-terminal domain-containing protein 1) (MOSC domain-containing protein 1) (Moco sulfurase C-terminal domain-containing protein 1)
1_MGAAG 6_ SSALA 11_ RFVLL 16_ AQSRP 21_ GWLGV 26_ AALGL 31_ TAVAL 36_ GAVAW 41_ RRAWP 46_ TRRRR 51_ LLQQV 56_ GTVAQ 61_ LWIYP 66_ VKSCK 71_ GVPVS 76_ EAECT 81_ AMGLR 86_ SGNLR 91_ DRFWL 96_ VINQE 101_ GNMVT 106_ ARQEP 111_ RLVLI 116_ SLTCD 121_ GDTLT 126_ LSAAY 131_ TKDLL 136_ LPIKT 141_ PTTNA 146_ VHKCR 151_ VHGLE 156_ IEGRD 161_ CGEAT 166_ AQWIT 171_ SFLKS 176_ QPYRL 181_ VHFEP 186_ HMRPR 191_ RPHQI 196_ ADLFR 201_ PKDQI 206_ AYSDT 211_ SPFLI 216_ LSEAS 221_ LADLN 226_ SRLEK 231_ KVKAT 236_ NFRPN 241_ IVISG 246_ CDVYA 251_ EDSWD 256_ ELLIG 261_ DVELK 266_ RVMAC 271_ SRCIL 276_ TTVDP 281_ DTGVM 286_ SRKEP 291_ LETLK 296_ SYRQC 301_ DPSER 306_ KLYGK 311_ SPLFG 316_ QYFVL 321_ ENPGT 326_ IKVGD 331_PVYLL
1: Catalyzes the reduction of N-oxygenated molecules, acting as a counterpart of cytochrome P450 and flavin-containing monooxygenases in metabolic cycles (PubMed:19053771, PubMed:21029045, PubMed:30397129). As a component of prodrug-converting system, reduces a multitude of N-hydroxylated prodrugs particularly amidoximes, leading to increased drug bioavailability (PubMed:19053771). May be involved in mitochondrial N(omega)-hydroxy-L-arginine (NOHA) reduction, regulating endogenous nitric oxide levels and biosynthesis (PubMed:21029045). Postulated to cleave the N-OH bond of N-hydroxylated substrates in concert with electron transfer from NADH to cytochrome b5 reductase then to cytochrome b5, the ultimate electron donor that primes the active site for substrate reduction (PubMed:19053771, PubMed:21029045)